Last reviewed · How we verify
Nicotine Mini
Nicotine Mini is a nicotine replacement therapy product that delivers nicotine through a small, discrete oral form to reduce cravings and withdrawal symptoms in smokers attempting to quit.
Nicotine Mini delivers nicotine through a miniaturized oral formulation to provide nicotine replacement therapy for smoking cessation. Used for Smoking cessation aid.
At a glance
| Generic name | Nicotine Mini |
|---|---|
| Also known as | Nicotine Mini-Lozenge |
| Sponsor | University of Wisconsin, Madison |
| Drug class | Nicotine replacement therapy |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Nicotine Mini works by binding to nicotinic acetylcholine receptors in the central nervous system, providing a controlled dose of nicotine that satisfies cravings without the combustion products of cigarettes. This allows smokers to gradually reduce their nicotine dependence while managing withdrawal symptoms such as irritability, anxiety, and difficulty concentrating. The mini formulation offers a convenient, portable alternative to traditional nicotine replacement therapies.
Approved indications
- Smoking cessation aid
Common side effects
- Mouth irritation
- Hiccups
- Nausea
- Headache
- Dizziness
Key clinical trials
- Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Mindfulness-based Smoking Cessation Enhanced With Mobile Technology (NA)
- Take A Break - Rural (NA)
- Determination of Liquid Flavor and Nicotine Form Outcomes (NA)
- Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. (PHASE3)
- TLR 9 (rs352140) Gene Polymorphism in Helicobacter Pylori Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine Mini CI brief — competitive landscape report
- Nicotine Mini updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI